全文获取类型
收费全文 | 9925篇 |
免费 | 1389篇 |
国内免费 | 189篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 154篇 |
妇产科学 | 9篇 |
基础医学 | 295篇 |
口腔科学 | 43篇 |
临床医学 | 622篇 |
内科学 | 799篇 |
皮肤病学 | 41篇 |
神经病学 | 389篇 |
特种医学 | 118篇 |
外国民族医学 | 1篇 |
外科学 | 227篇 |
综合类 | 1166篇 |
预防医学 | 123篇 |
眼科学 | 6177篇 |
药学 | 644篇 |
6篇 | |
中国医学 | 287篇 |
肿瘤学 | 367篇 |
出版年
2024年 | 26篇 |
2023年 | 205篇 |
2022年 | 230篇 |
2021年 | 398篇 |
2020年 | 411篇 |
2019年 | 368篇 |
2018年 | 469篇 |
2017年 | 411篇 |
2016年 | 482篇 |
2015年 | 450篇 |
2014年 | 592篇 |
2013年 | 747篇 |
2012年 | 642篇 |
2011年 | 650篇 |
2010年 | 490篇 |
2009年 | 531篇 |
2008年 | 480篇 |
2007年 | 497篇 |
2006年 | 473篇 |
2005年 | 369篇 |
2004年 | 342篇 |
2003年 | 253篇 |
2002年 | 212篇 |
2001年 | 187篇 |
2000年 | 185篇 |
1999年 | 148篇 |
1998年 | 130篇 |
1997年 | 82篇 |
1996年 | 73篇 |
1995年 | 82篇 |
1994年 | 72篇 |
1993年 | 65篇 |
1992年 | 84篇 |
1991年 | 49篇 |
1990年 | 58篇 |
1989年 | 67篇 |
1988年 | 41篇 |
1987年 | 28篇 |
1986年 | 28篇 |
1985年 | 82篇 |
1984年 | 60篇 |
1983年 | 49篇 |
1982年 | 44篇 |
1981年 | 53篇 |
1980年 | 48篇 |
1979年 | 22篇 |
1978年 | 18篇 |
1977年 | 11篇 |
1976年 | 6篇 |
1975年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
21.
Irmak Karaca Suzan Güven Yılmaz Melis Palamar Halil Ateş 《Ocular immunology and inflammation》2020,28(6):947-951
ABSTRACT
Purpose
To investigate the effect of 1% tropicamide on anterior chamber aqueous flare (ACAF) measurements acquired with laser flare meter in patients with pseudoexfoliation. 相似文献22.
刘汶 《中国中医药现代远程教育》2020,(4):99-103
胃食管反流病多因饮食不节、七情失和、素体禀赋虚弱等原因,导致脾胃受损,土壅木郁,肝胃不和,胃失和降,胃气上逆,出现反酸、烧心、嗳气、胃胀等症状。其发生与肝、脾、胃密切相关,气机逆乱,胃失和降是其基本病机。由于本病病程较长,病情易反复发作,易成为顽固性胃食管反流病。而顽固性胃食管反流病多为本虚标实之证,本虚是指因疾病反复发作所导致的脾胃虚弱,标实是指由于脾胃虚弱、脾失健运、土壅木郁、气机不畅所导致的痰湿、气滞、热郁、血瘀等实邪。最后结局是痰气郁(瘀)交阻,脾胃升降失司,胃气上逆,从而引起反酸烧心反复发作,缠绵难愈。纵观核心病机,乃"气郁"、"痰阻"导致的胃失和降、胃气上逆。治疗顽固性胃食管反流病时宜"从气而治""从痰而治"。 相似文献
23.
Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield 下载免费PDF全文
24.
目的:观察青光眼引流钉植入术治疗难治性青光眼的疗效.方法:对联合应用抗青光眼药物无法控制的难治性开角型青光眼1 9例19只眼行青光眼引流钉植入术,术中应用丝裂霉素(2 mg/6~8 mL,2.5~4 min)及可松解缝线.术后1天、2周和1、3、6、12个月进行随访,观察眼压、视力、滤过泡形态、前房深度、眼底C/D、降眼压药物使用情况、完全及部分成功率及有无并发症等情况.结果:19例患者中,术后完全成功率78.9%(1 5例),部分成功率10.5%(2例),失败10.5%(2例).术前用3~5种降眼压药,眼压控制于27.7±10.1 mmHg.术后随访仅三人需使用1~2种降压药物.眼压下降组间有显著性意义(P<0.001).与术前相比,术后1天(11.8±7.7 mmHg,P<0.001),术后2周(10.1-±4.2 mmHg,P<0.05),1个月(12.0±4.0 mmHg,P=0.001),6个月(12.2±3.4 mmHg,P<0.001),1年(13.1±3.3 mmHg,P=0.001)及2年随访(14.5±2.5 mmHg,P=0.001),眼压下降均具有显著性意义.术后患者视力、前房深度及C/D改变差异无显著性意义.末次随访滤过泡弥散隆起57.9%(11例),微囊型15.8%(3例),瘢痕型21.1%(4例),包裹型5.3%(1例).所有患者均未观察到明显的术后并发症的发生.结论:房水引流钉植入术治疗难治性开角型青光眼手术成功率高,并发症少,值得推广. 相似文献
25.
《Survey of ophthalmology》2019,64(4):486-497
Glaucoma, a progressive optic neuropathy, is the leading cause of irreversible blindness worldwide. Glaucoma patients are usually initially managed with medications and laser therapies, before more invasive ocular surgeries. For laser treatments of glaucoma, laser trabeculoplasty and laser transscleral cyclophotocoagulation lower the intraocular pressure by increasing the aqueous outflow and decreasing the aqueous production, respectively. The development of a subthreshold laser technique, the micropulse laser, has been investigated as a potential alternative to traditional glaucoma laser procedures, with an aim to further decrease the risk of side effects without compromising the laser treatments' efficacy. Few reviews have been done on the 2 current micropulse laser treatments for glaucoma—micropulse laser trabeculoplasty and micropulse transscleral cyclophotocoagulation. Hence, the purpose of this review was to assess the efficacy and safety of micropulse laser techniques in the treatment of glaucoma. 相似文献
26.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(8):509-518
BackgroundIn the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed.Patients and MethodsEligible patients had received ≥ 1 line of treatment and were administered bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for 8 cycles with or without daratumumab (16 mg/kg) until disease progression.ResultsOf 498 patients in the intent-to-treat (ITT) population (D-Vd, n = 251; Vd, n = 247), 47% had 1 prior line of treatment (1PL; D-Vd, n = 122; Vd, n = 113). Median progression-free survival (PFS) was significantly prolonged with D-Vd versus Vd in the ITT population (16.7 vs. 7.1 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.25-0.40; P < .0001) and the 1PL subgroup (27.0 vs. 7.9 months; HR, 0.22; 95% CI, 0.15-0.32; P < .0001). In lenalidomide-refractory patients, the median PFS was 7.8 versus 4.9 months (HR, 0.44; 95% CI, 0.28-0.68; P = .0002) for D-Vd (n = 60) versus Vd (n = 81). Minimal residual disease (MRD)–negativity rates (10−5) were greater with D-Vd versus Vd (ITT: 14% vs. 2%; 1PL: 20% vs. 3%; both P < .0001). PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001). No new safety concerns were observed.ConclusionAfter 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates. 相似文献
27.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
28.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
29.
30.
目的:探讨超高CD34+采集的动员方案后序贯二次自体造血干细胞移植治疗难治性霍奇金淋巴瘤的疗效和安全性。方法:对1例经过多疗程一线、二线、新药、免疫等均难治的霍奇金淋巴瘤患者,予以IA+C方案化疗+G-CSF动员干细胞后采集出超高水平CD34+细胞,之后行自体造血干细胞移植,移植后获得完全缓解,再予序贯第二次自体造血干细胞移植进行巩固治疗。结果:总计输注单个核细胞数13.67×108/kg,CD34+细胞48.68×106/kg,第一次自体造血干细胞移植术后第7天造血功能恢复,复查全身PET-CT提示获得完全缓解,第二次自体造血干细胞移植术后第8天造血功能恢复,两次自体造血干细胞移植相关并发症均在可控范围内。结论:超高CD34+细胞采集的IA+C方案化疗+G-CSF动员可以让患者有机会进行多次自体造血干细胞移植,是临床动员的创新方案。对于难治性霍奇金淋巴瘤,序贯二次自体造血干细胞移植可达到更深层次缓解,且安全性较高,延长患者无疾病生存期及总生存期,为难治性霍奇金淋巴瘤治疗提供更多临床依据。 相似文献